ClinicalTrials.gg
Sign In

Drug

Hepatitis B Virus Antisense Oligonucleotide AHB-137 clinical trials

Also written AHB-137.

studies test it
9
open now
4
in phase 3
1
first study started
2023

Keep track of what changes. Save the Hepatitis B Virus Antisense Oligonucleotide AHB-137 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

AHB-137 injection
3

Development codes

AHB-137
5

Studies by the year they started

9 studies that test it; most in 2026 (4)

Studies that test Hepatitis B Virus Antisense Oligonucleotide AHB-137, by start year
YearStudies
20232
20241
20252
20264

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
6
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Hepatitis B, Chronic
9

Who runs them

Industry 9 · Other 0

Ausper Biopharma Co., Ltd. (6) · AusperBio Therapeutics Inc. (3)

Studies

Open first, then newest update. How each study uses Hepatitis B Virus Antisense Oligonucleotide AHB-137 is read from its arms, and is right about nine times in ten.

Testing it · 9

Given in every arm · 4 — Hepatitis B Virus Antisense Oligonucleotide AHB-137 is usual care beside what is tested